In what situations would you consider ESAs in hospitalized patients with severe anemia for indications other than CKD or myelosuppressive chemotherapy (e.g., ACD, hemorrhage)?

In deciding on the risk-benefit of ESAs in patients with severe anemia due to bleeding and/or inflammatory disease, there are two considerations. The first is the severity of the anemia and consequently, the time to initial response. Using the standard dose of ESAs, it may take 8 to 12 weeks to achi...